Immunomodulatory antibody drug conjugates binding to a human mica polypeptide

Patent metadata

Field	Value
Publication number	US-2020023071-A1
Application number	US-201816483758-A
Country	US
Kind code	A1
Filing date	Feb 5, 2018
Priority date	Feb 6, 2017
Publication date	Jan 23, 2020
Grant date	—

Abstract

The present invention provides antigen-binding proteins capable of binding to human MICA polypeptides, conjugated to cytotoxic agents. Said conjugates have increased activity in the treatment of disorders characterized by MICA-expressing cells, particularly tumor cells.

First claim

1 - 48 . (canceled)

49 . A method of treating an individual having a cancer characterized by MICA-expressing cells, comprising administering to the individual an antigen binding protein having the structure of formula I:
Ab-(X-Z) m   (formula I)
or a pharmaceutically acceptable salt or solvate thereof, wherein, Ab is an antibody or antibody fragment that binds a human MICA polypeptide, wherein the antibody or antibody fragment lacks an Fc domain or comprises an Fc domain of human origin that is modified to reduce binding to a human Fey receptor; X is a moiety which connects Ab and Z; Z comprises a DNA minor groove binding agent; and m is 2.

50 . The method of claim 49 , wherein the antibody comprises an Fc domain of IgG1 isotype that lacks binding to human Fcγ receptors human CD16A, CD16B, CD32A, CD32B and CD64, wherein the Fc domain comprises an amino acid substitution at Kabat residue(s) 234, 235, 237, 297, 330 and/or 331.

51 . The method of claim 50 , wherein the Fe domain comprises L234A/L235E/N297X/P331S substitutions, L234F/L235E/N297X/P331S substitutions, L234A/L235E/G237A/N297X/P331S substitutions, or L234A/L235E/G237A/N297X/A330S/P331S substitutions, wherein X is any amino acid other than an asparagine.

52 . The method of claim 49 , wherein the antibody comprises a functionalized acceptor glutamine at Kabat residue 295 and/or 297 of each heavy chain.

53 . The method of claim 49 , wherein the cancer is a colorectal cancer, renal cell carcinoma, lung cancer, melanoma, ovarian cancer, endometrial cancer, pancreatic cancer or a head and neck cancer.

54 . The method of claim 49 , wherein the treatment is capable of causing the death of MICA-expressing tumor cells without inducing an increase in soluble MICA in circulation.

55 . The method of claim 49 , wherein the antigen binding protein is administered in an amount between 0.01 and 0.1 mg/kg body weight.

56 . The method of claim 49 , wherein the antigen binding protein is administered in an amount between 0.01 and 0.2 mg/kg body weight.

57 . An antigen binding protein having the structure of formula I:
Ab-(X-Z) m   (formula I)
or a pharmaceutically acceptable salt or solvate thereof, wherein, Ab is an antibody or antibody fragment that binds a human MICA polypeptide, wherein the antibody or antibody fragment lacks an Fc domain or comprises an Fc domain of human origin that is modified to reduce binding to a human Fcγ receptor; X is a moiety which connects Ab and Z; Z comprises a DNA minor groove binding agent; and m is 2.

58 . The antigen binding protein of claim 57 , wherein X comprises a linker that is cleaved by an intracellular peptidase or protease enzyme, optionally, a lysosomal or endosomal protease.

59 . The antigen binding protein of claim 57 , wherein the antibody or antibody fragment comprises a functionalized amino acid residue (B) comprising the structure:
(B)-L″-Y-Z
or a pharmaceutically acceptable salt or solvate thereof, wherein: B is an amino acid residue present within or appended to a constant region of the antibody or antibody fragment; L″ is a linker covalently bonded to the amino acid residue B; Y is a spacer system; and Z comprises a DNA minor groove binding agent.

60 . The antigen binding protein of claim 57 , wherein the antibody or antibody fragment comprises a functionalized amino acid residue (B) comprising the structure comprising the structure:
(B)-L″-RR′—Y-Z
or a pharmaceutically acceptable salt or solvate thereof, wherein: B is an amino acid residue present within or appended to a constant region of the antibody or antibody fragment; L″ is a linker covalently bonded to the amino acid residue B; (RR′) is an addition product between a reactive moiety R and a complementary reactive moiety R′; Y is a spacer system; and Z comprises a DNA minor groove binding agent.

61 . The antigen binding protein of claim 57 , wherein Z is a pyrrolobenzodiazepine dimer.

62 . The antigen binding protein of claim 57 , wherein the antigen binding protein competes for binding to the same epitope on MICA and/or MICB as an antibody selected from the group consisting of: 19E9, 18E8, 9C10 or 6E4.

63 . The antigen binding protein of claim 57 , wherein the antigen binding protein is an antibody or antibody fragment comprising a functionalized acceptor glutamine residue (Q) comprising the structure:
(Q)-L″-Y-Z
or a pharmaceutically acceptable salt or solvate thereof, wherein: Q is a glutamine residue present within or appended to a constant region of the antibody or antibody fragment; L″ is a lysine-based linker in which the nitrogen atom is covalently bonded to the γ carbon of Q as a secondary amine; Y is a spacer system; and Z comprises a cytotoxic agent, optionally a DNA minor groove binding agent, optionally a pyrrolobenzodiazepine.

64 . The antigen binding protein of claim 57 , wherein the antibody comprises an Fc domain of IgG1 isotype that has decreased binding to human Fcγ receptors human CD16A, CD16B, CD32A, CD32B and CD64, wherein the Fc domain comprises an amino acid substitution at Kabat residue(s) 234, 235, 237, 297, 330 and/or 331.

65 . The antigen binding protein of claim 64 , wherein the Fc domain comprises L234A/L235E/N297X/P331S substitutions, L234F/L235E/N297X/P331S substitutions, L234A/L235E/G237A/N297X/P331S substitutions, or L234A/L235E/G237A/N297X/A330S/P331S substitutions, wherein X is any amino acid other than an asparagine.

66 . A composition comprising a plurality of immunoconjugates according to claim 57 , wherein the composition is characterized by a ratio of cytotoxic agent moieties to antibody molecules (drug:antibody ratio) of 1.8 to 2.0.

Assignees

• Innate Pharma

Inventors

• Blery Mathieu
• Bregeon Delphine
• Gauthier Laurent
• Lhospice Florence
• Pouyet Laurent

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/2833 Primary

  against MHC-molecules, e.g. HLA-molecules · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• A61K47/6849 Primary

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title